Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4- thiazolidinones as cycloxygenase/lipoxygenase inhibitors

European Journal of Medicinal Chemistry

Volumn 47, Issue 1, 2012, Pages 111-124

  Eleftheriou, Phaedra ^b   Geronikaki, Athina ^a   Hadjipavlou Litina, Dimitra ^a   Vicini, Paola ^c   Filz, Olga ^d   Filimonov, Dmitry ^d   Poroikov, Vladimir ^d   Chaudhaery, Shailendra S ^e   Roy, Kuldeep K ^e   Saxena, Anil K ^e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^c UNIVERSITY OF PARMA   (Italy)

^d INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^e CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Benzo benzisothiazolidinones; COX 1 2 inhibitors; Fragment based drug design; Inflammation; Lipoxygenase inhibitors; Multi target drugs

Indexed keywords

2 (BENZO[D]ISOTHIAZOL 3 YLIMINO) 5 (4 CHLORO BENZYLIDENE)THIAZOLIDIN 4 ONE; 2 (BENZO[D]ISOTHIAZOL 3 YLIMINO) 5 (4 HYDROXY 3,5 DIMETHOXYBENZYLIDENE)THIAZOLIDIN 4 ONE; 2 (BENZOTHIAZOL 2 YLIMINO) 5 (2 NITRO BENZYLIDENE)THIAZOLIDIN 4 ONE; 2 (HETEROARYLIMINO)THIAZOLIDIN 4 ONE; 2 HETEROARYLIMINO 5 BENZYLIDENE 4 THIAZOLIDINONE; 4 THIAZOLIDINONE DERIVATIVE; 5 (2 CHLORO BENZYLIDENE) 2 (BENZO[D]THIAZOL 2 YLIMINO)THIAZOLIDIN 4 ONE; 5 (3 HYDROXYBENZYLIDENE) 2 (BENZO[D]THIAZOL 2 YLIMINO)THIAZOLIDIN 4 ONE; 5 (4 HYDROXY 3,5 DIMETHOXYBENZYLIDENE) 2 (BENZO[D]THIAZOL 2 YLIMINO)THIAZOLIDIN 4 ONE; ANTIINFLAMMATORY AGENT; BENZOTHIAZOLE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NAPROXEN; NORDIHYDROGUAIARETIC ACID; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PAW EDEMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CATALYTIC DOMAIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; EDEMA; FEMALE; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; MALE; MICE; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES;

EID: 84855817756     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.10.029     Document Type: Article

References (65)

1. C. Melchiorre, M.L. Bolognesi, A. Minarini, M. Rosini, and V. Tumiatti Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy J. Med. Chem. 53 2010 5906 5914
2. R. Morphy, and Z. Rankovic Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 48 2005 6523 6543
3. C. Wermuth Multitargeted drugs: the end of the "one-target-one disease" philosophy? Drug Disc. Today 9 2004 826 827
4. P. Csermely, V. Agoston, and S. Pongor The efficiency of multi-target drugs: the network approach might help drug design Trends Pharmacol. Sci. 26 2005 178 182
5. J. Lehar, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, E.R. Price, R.J. Rickles, G.F. Short, J.E. Staunton, X. Jin, M.S. Lee, G.R. Zimmermann, and A.A. Borisy Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 27 2009 659 666
6. J. Rodon, J. Perez, and R. Kurzrock Combining targeted therapies: practical issues to consider at the bench and bedside Oncologist 15 2010 37 50
7. J. Minnerup, and W.-R. Schabitz Multifunctional actions of approved and candidate stroke drugs Neurotherapeutics 6 2009 43 52
8. M.J. Milan Dual- and triple-acting agents for treatment core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 6 2009 53 77
9. C.R. Rodrigues, M.P. Veloso, H. Verli, C.A. Fraga, A.L. Miranda, and E.J. Barreiro Selective PGHS-2 inhibitors: a rational approach for treatment of the inflammation Curr. Med. Chem. 9 2002 849 867
10. R. Ottana, R. Maccari, M.T. Barreca, G. Bruno, A. Rotondo, A. Rossi, G. Chiricosta, R. Paola, L. Sautebin, S. Cuzzocrea, and M.G. Vigorita 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents Bioorg.Med. Chem. 13 2005 4243 4252
11. T.D. Venu, S. Shashikanth, S.A. Khanum, S. Naveen, A. Firdouse, M.A. Sridhar, and J.S. Prasad Synthesis and crystallographic analysis of benzophenone derivatives - the potential anti-inflammatory agents Bioorg. Med.Chem. 15 2007 3505 3514
12. X. Leval, F. Julémont, J. Delarge, B. Pirotte, and J.-M. Dogné New trends in dual 5-LOX/COX inhibition Curr. Med. Chem. 9 2002 941 962
13. J.F. Penrose, K.F. Austen, and B.K. Lam Leukotrienes: biosynthetic pathways, release and receptor-mediated actions with relevance to disease states J.L. Gallin, R. Snyderman, Inflammation Basic Principles and Clinical Correlates 1999 Lippicort Williams & Wilkins Philadelphia 361 372
14. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu. Rev. Pharmacol. Toxicol. 38 1998 97 120
15. J. Martel-Pelletier, D. Lajeunesse, P. Reboul, and J.-P. Pelletier Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs Ann. Rheum. Dis. 62 2003 501 509
16. J.Y. Jouzeau, B. Terlain, A. Abid, E. Nedelec, and P. Netter Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs Drugs 53 1997 563 582
17. M. Bayes, X. Rabasseda, and J.R. Prous Gateways to clinical trials Methods Find. Exp. Clin. Pharmacol. 24 8 2002 525 551
18. P.N. Rao, Q.H. Chen, and E.E. Knaus Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases J. Med. Chem. 49 5 2006 1668 1683
19. M. Scholz, H.K. Ulbrich, and G. Dannhardt Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles Eur. J. Med. Chem. 43 2008 1152 1159
20. E. Pontiki, D. Hadjipavlou-Litina, K. Litinas, O. Nicolotti, and A. Carotti Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities Eur. J. Med. Chem. 46 2011 191 200
21. Yue Li, Shu-Han Chen, Tian-Miao Ou, Jia-Heng Tan, Ding Li, Lian-Quan Gu, and Zhi-Shu Huang Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase Bioorg. Med.Chem. 19 2011 2074 2083
22. A.A. Geronikaki, A.A. Lagunin, D.I. Hadjipavlou-Litina, P.T. Elefteriou, D.A. Filimonov, V.V. Poroikov, I. Alam, and A.K. Saxena Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition J. Med. Chem. 51 2008 1601 1609
23. M. Fischer, and R.E. Hubbard Fragment-based ligand discovery Mol. Interventions. 9 2009 23 30
24. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
25. Y. Cao, T. Jiang, and T. Girke A maximum common substructure-based algorithm for searching and predicting drug-like compounds Bioinformatics 24 2008 366 374
26. J. Masciocchi, G. Frau1, M. Fanton, M. Sturlese, M. Floris, L. Pireddu, P. Palla, F. Cedrati, P. Rodriguez-Tome, and S. Moro MMsINC: a large-scale chemoinformatics database Nucleic Acids Res. 37 2009 284 290
27. Q.S. Du, R.B. Huang, Y.T. Wei, Z.W. Pang, L.Q. Du, and K.C. Chou Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design J. Comput. Chem. 30 2009 295 304
28. B.M. Spowage, C.L. Bruce, and J.D. Hirst Interpretable correlation descriptors for quantitative structure-activity relationships J. Cheminf. 1 2009
29. M.A.C. Pérez, M.B. Sanz, L.R. Torres, R.G. Ávalos, M. Pérez González, and H. González Díaz A topological sub-structural approach for predicting human intestinal absorption of drugs Eur. J. Med. Chem. 39 2004 905 916
30. D. Livingstone Data Analysis for Chemists 1995 Oxford University Press Oxford
31. D.A. Filimonov, and V.V. Poroikov Probabilistic approach in activity prediction A. Varnek, A. Tropsha, Chemoinformatics Approaches to Virtual Screening 2008 RSC Publishing Cambridge (UK) 182 216
32. A. Geronikaki, D. Druzhilovsky, A. Zakharov, and V. Poroikov Computer-aided predictions for medicinal chemistry via Internet SAR QSAR Environ. Res. 19 2008 27 38
33. A.A. Lagunin, O.A. Gomazkov, D.A. Filimonov, T.A. Gureeva, E.A. Dilakyan, E.V. Kugaevskaya, Y.E. Elisseeva, N.I. Solovyeva, and V.V. Poroikov Computer-aided selection of potential antihypertensive compounds with dual mechanisms of action J. Med. Chem. 46 2003 3326 3332
34. X.Q. Lewell, D.B. Judd, S.P. Watson, and M.M. Hann RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comput. Sci. 38 3 1998 511 522
35. J. Degen, and M. Rarey FlexNovo: structure-based searching in large fragment spaces Chem. Med. Chem. 1 2006 854 868
36. D. Douguet, H. Munier-Lehmann, G. Labesse, and S. Pochet LEA3D: a computer-aided ligand design for structure-based drug design J. Med. Chem. 48 2005 2457 2468
37. C.A. Nicolaou, J. Apostolakis, and C.S. Pattichis De novo drug design using multiobjective evolutionary graphs J. Chem. Inf. Model. 49 2009 295 307
38. A.S. Tarendash Let's Review Chemistry, the Physical Setting fourth ed. 2006 Barron's Educational Series New York 228-242
39. P.S. Kutchukian, and E.I. Shakhnovich De novo design: balancing novelty and confined chemical space Expert Opin. Drug Discov. 5 2010 789 812
40. P. Vicini, A. Geronikaki, M. Incerti, F. Zani, J.C. Dearden, and M. Hewitt Heteroarylimino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidene-4-thiazolidinones with antimicrobial activity: synthesis and structure-activity relationship Bioorg. Med. Chem. 16 7 2008 3714 3724
41. P. Vicini, A. Geronikaki, A. Kitka, M. Incerti, and F. Zani Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones Bioorg. Med. Chem. 14 2006 3859 3864
42. A. Geronikaki, and G. Theophilidis Synthesis of 2-(aminoacetylamino) thiazole derivatives and comparison of their local anaesthetic activity by method of action potential Eur. J. Med. Chem. 27 1992 709 716
43. C. Papadopoulou, A. Geronikaki, and D. Hadjipavlou-Litina Synthesis and biological evaluation of new thiazolyl/benzothiazolyl-amides, derivatives of 4-phenyl-piperazine Farmaco 60 2005 969 973
44. O. Kouatli, P. Zoumpoulakis, Ch. Camoutsis, M. Soković, A. Ćirić, J. Glamočlija, and A. Geronikaki Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs Bioorg. Med. Chem. 18 2010 426 432
45. GOLD, Version 2.2; Cambridge Crystallographic Data Centre: Cambridge, UK.
46. D. Picot, P.J. Loll, and R.M. Garavito The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 Nature 367 1994 243 249
47. S. Mittal, A. Malde, C. Selvam, K.S. Arun, P.S. Johar, S.M. Jachak, P. Ramarao, P.V. Bharatam, and H.P.S. Chawla Synthesis and evaluation of S-4-(3-thienyl)phenyl-α-methylacetic acid Bioorg. Med. Chem. Lett. 14 2004 979 982
48. M. Lindner, W. Sippl, and A. Radwan Pharmacophore Elucidation and molecular docking studies on 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3- carboxylic acid derivatives as COX-2 inhibitors Sci. Pharm. 78 2010 195 214
49. Md. J. Uddin, P.N. Praveen Rao, and E.E. Knaus Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors Bioorg. Med. Chem. Lett. 14 2004 1953 1956
50. Md. J. Uddin, P.N. Praveen Rao, R. McDonald, and E.E. Knaus A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors J. Med. Chem. 47 2004 6108 6111
51. Hye-Jung Kim, Chong Hak Chae, Kyu Yang Yi, Kyung-Lae Park, and Sung-eun Yoo Computational studies of COX-2 inhibitors: 3D-QSAR and docking Bioorg. Med. Chem. 12 2004 1629 1641
52. J.L. Wang, D. Limburg, M.J. Graneto, J. Springer, J.R.B. Hamper, S. Liao, J.L. Pawlitz, R.G. Kurumbail, T. Maziasz, J.J. Talley, J.R. Kiefer, and J. Carter The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life Bioorg. Med. Chem. Lett. 20 2010 7159 7163
53. R.G. Kurumbail, A.M. Stevens, J.K. Gierse, J.J. McDonald, R.A. Stegeman, J.Y. Pak, D. Gildehaus, J.M. Miyashiro, T.D. Penning, K. Seibert, P.C. Isakson, and W.C. Stallings Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 384 1996 644 648
54. S.W. Rowlinson, J.R. Kiefer, J.J. Prusakiewicz, J.L. Pawlitz, K.R. Kozak, A.S. Kalgutkar, W.C. Stallings, R.G. Kurumbail, and L.J. Marnett A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385 J. Biol. Chem. 278 2003 45763 45769
55. A.L. Blobaum, and L.J. Marnett Structural and functional basis of cyclooxygenase inhibition J. Med. Chem. 50 2007 1225 1441
56. AR Brash Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate J. Biol. Chem. 274 1999 23679 23682
57. D. Shibata, and B. Axelrod Plant lipoxygenases J. Lipid Mediat Cell Signal. 12 1995 213 228
58. W. Minor, J. Steczko, B. Stec, Z. Otwinowski, J.T. Bolin, R. Walter, and B. Axelrod Crystal structure of soybean lipoxygenase L-1 at 1.4 resolution Biochemistry 35 1996 10687 10701
59. S.T. Prigge, J.C. Boyington, M. Faig, K.S. Doctor, B.J. Gaffney, and L.M. Amzel Structure and mechanism of lipoxygenases Biochimie 79 1997 629 636
60. P. Aparoy, R.N. Reddy, Lalitha Guruprasad, M.R. Reddy, and P. Reddanna Homology modeling of 5-lipoxygenase and hints for better inhibitor design J. Comput. Aided Mol. Des. 22 2008 611 619
61. R.K. Somvanshi, A.K. Singh, M. Saxena, B. Mishra, and S. Dey Development of novel peptide inhibitor of lipoxygenase based on biochemical and BIAcore evidences Biochim. Biophys. Acta 1784 2008 1812 1817
62. D. Lapenna, G. Ciofani, S.D. Pierdomenico, M. Neri, C. Cuccurullo, M.A. Giamberardino, and F. Cuccurullo Inhibitory activity of salicylic acid on lipoxygenase-dependent lipid peroxidation Biochim. Biophys. Acta 1790 2009 25 30
63. I.B. Taraporewala, and J.M. Kauffman Synthesis and structure-activity relationships of anti-inflammatory 9,10-dihydro-9-oxo-2-acridinealkanoic acids and 4-(2-carboxyphenyl)aminobenzenealkanoic acids J. Pharm. Sci. 79 2 1990 173 178
64. S.A. Gillmor, A. Villaseñor, R. Fletterick, E. Sigal, and M.F. Browner The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity Nat. Struct. Biol. 4 1997 1003 1009
65. Schrödinger, Version 8.0 2005 Schrödinger, LLC New York